

The 13<sup>th</sup> Asia-Pacific Primary Liver Cancer Expert Meeting

Novel Insights into the Evolution of Liver Cancer Management July 6-8, 2023 | Grand InterContinental Seoul Parnas, Seoul, Korea

New Preoperative CT Staging of Intrahepatic Cholangiocarcinoma: Impact of Up-staging of Tumor Multiplicity on Survival Outcomes

Yeun-Yoon Kim, MD, PhD<sup>1</sup>, Hye Jung Shin, MS<sup>2</sup>, Suk-Keu Yeom, MD, PhD<sup>3</sup>, Sang Hyun Choi, MD, PhD<sup>4</sup>, Hyungjin Rhee, MD, PhD<sup>1</sup>, Ji Hoon Park, MD, PhD<sup>5</sup>, Eun-Suk Cho, MD, PhD<sup>6</sup>, Sumi Park, MD, PhD<sup>7</sup>, Seung Soo Lee, MD, PhD<sup>4</sup>, Mi-Suk Park, MD, PhD<sup>1⊠</sup>


<sup>1</sup>Department of Radiology, Severance Hospital, Yonsei University College of Medicine, Seoul, <sup>2</sup>Biostatistics Collaboration Unit, Department of Biomedical Systems Inform atics, Yonsei University College of Medicine, Seoul, <sup>3</sup>Department of Radiology, Korea University Ansan Hospital, Korea University College of Medicine, Seoul, <sup>4</sup>Departmen t of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, <sup>5</sup>Department of Radiology, Seoul National Univer sity Bundang Hospital, Gyeonggi-do, <sup>6</sup>Department of Radiology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, <sup>7</sup>Department of Radiology, National Health Insurance Service Ilsan Hospital, Goyang, Republic of Korea

# Background

- **Tumor multiplicity** has been emphasized as an indicator of **advanced-stage** cancer rather than early-stage (i.e., T2, as defined by the eighth edition AJCC) cancer.
- There has been considerable debate as to whether multiple tumors should be considered as metastatic or locally advanced disease.
  - One of the reasons for this controversy is that the 2 categories of multiple tumors, that is, **satellitosis or multifocal tumors**, have been both defined as intrahepatic metastasis in the previous study.
  - Identification of suitable candidates for surgery remains crucial in patients with multiple intrahepatic tumors, and subdividing the multiple tumors category in cancer staging may have prognostic significance when planning curative surgical treatment.

# Background / Aim

- The current eighth edition AJCC staging system is based on postoperative pathology and may be suboptimal in the preoperative setting.
  - CT is the primary imaging modality for preoperative staging of intrahepatic and extrahepatic diseases.
- We aimed to develop and validate a **preoperative CT staging system** for iCCA adapted from the eighth edition AJCC staging system in a multi-institutional cohort from South Korea, focusing on **tumor multiplicity**.



APPLE The 13th Asia-Pacific Primary Liver Cancer Expert Meeting

#### Cox regression analysis of preoperative CT parameters for OS Cox proportional hazards regression was performed to identify independent staging predictors of OS, and the staging system was modified accordingly.

	Univariable		Multivariable	
Variable	HR (95% CI)	P value	HR (95% CI)	<i>P</i> value
AJCC staging parameters				
Solitary tumor ≤5 cm without vascular invasion (T1a)	1 (Reference)		1 (Reference)	
Solitary tumor >5 cm (T1b)	1.66 (0.75–3.71)	0.213	1.49 (0.67-3.35)	0.331
Intrahepatic vascular invasion or multiple tumors (T2)	2.90 (1.93-4.35)	<0.001	2.55 (1.68-3.89)	< 0.001
Visceral peritoneal perforation (T3)	2.74 (1.87-4.02)	<0.001	2.40 (1.61-3.59)	<0.001
Local extrahepatic structure invasion (T4)	5.23 (2.87–9.53)	<0.001	4.40 (2.37-8.16)	< 0.001
Lymph node metastasis (N1)	2.08 (1.55-2.80)	<0.001	1.46 (1.07–2.00)	0.017
Modified staging parameters				
Solitary tumor	1 (Reference)		1 (Reference)	
Intrahepatic vascular invasion	2.16 (1.40-3.34)	0.001	1.98 (1.27-3.09)	0.003
Visceral peritoneal perforation	2.16 (1.44-3.22)	<0.001	2.00 (1.32-3.01)	0.001
Satellitosis	3.55 (2.21-5.70)	<0.001	3.03 (1.84–5.00)	< 0.001
Multifocal tumors	4.55 (2.69–7.68)	<0.001	3.92 (2.27-6.77)	<0.001
Local extrahepatic structure invasion	4.88 (2.71-8.77)	<0.001	4.24 (2.32-7.77)	< 0.001
Lymph node metastasis	2.08 (1.55-2.80)	< 0.001	1.39 (1.01-1.91)	0.045




### Definition of the staging systems

AJCC 8th staging				Modified staging				
T staging								
T1a: solitary tumor ≤5 cm without vascular invasion				T1: solitary tumor without vascular invasion				
T1b: solitary tumor >5 cm without vascular invasion				11. sontary tumor without vascular invasion				
T2: solitary tumor with intrahepatic vascular invasion or multiple tumors with or without vascular invasion				T2: solitary tumor with intrahepatic vascular invasion or visceral peritoneal perforation				
T2. tumor porferating the subserval position open				T3a: the presence of satellitosis				
T3: tumor perforating the visceral peritoneum			T3b: the presence of multifocal tumors					
T4: tumor involving local extrahepatic structures by direct invasion				T4: tumor involving local extrahepatic structures by direct invasion				
TNM staging								
Т	Ν	М	Stage	Т	Ν	М	Stage	
Tla	N0	M0	IA	T1	N0	M0	I	
T1b	N0	M0	IB	T2	N0	M0	п	
T2	N0	M0	Ш	T3a	NO	M0	IIIA	
T3	N0	M0	IIIA	T3b	N0	M0	IIIB	
T4	N0	M0	IIIB	T4	NO	M0	IIIC	
Any T	N1	M0	IIIB	Any T	N1	M0	IIIC	



## **Overall Survival – development cohort**

- Our modified system provided better stratification of OS probabilities than the current system using preoperative CT staging.
  - AJCC T2 and T3 did not discriminate the survival curves on preoperative CT (log-rank *P* for T2 vs. T3 = .81; 5-year OS, 23.4% vs. 26.8%), but modified T2 gave better OS outcomes than modified T3a or T3b (log-rank *P* for T2 vs. T3a vs. T3b = .003; 5-year OS, 33.8% vs. 8.4% vs. 4.8%).
  - The Kaplan-Meier curves using TNM staging showed better stratification of stages II and III using the modified system (log-rank *P* for II vs. III; AJCC, *P* = .74; modified system, *P* = .003).



Kaplan-Meier curves for predicting OS in the development cohort with preoperative CT staging

using (A) AJCC T staging, (B) modified T staging, (C) AJCC TNM staging, and (D) modified TNM staging.

(c)

## **Overall Survival – validation cohort**

- Our modified system, but not the current system, showed statistically significant differences in the survival probability on preoperative CT in the validation cohort (log-rank P = .03; log-rank P for T2 vs. T3a vs. T3b = .04).
- The **Harrell C-indexes** of the modified system were comparable to those of the current system for predicting OS preoperatively in the development cohort and in the validation cohort.

	AJCC 8th staging	Modified staging	P value					
Development cohort								
Т	0.626 (0.585, 0.666)	0.647 (0.608, 0.686)	0.061					
TNM (3-tier)	0.614 (0.575, 0.654)	0.636 (0.596, 0.675)	0.069					
Validation cohort								
Т	0.662 (0.482, 0.842)	0.745 (0.590, 0.899)	0.248					
TNM (3-tier)	0.719 (0.610, 0.829)	0.739 (0.592, 0.886)	0.737					

# Conclusion

- Our new, modified preoperative CT staging system, which **upstages and subdivides tumor multiplicity**, can improve prognostic discrimination in patients with iCCA.
- This new staging system may be more useful than the current eighth edition AJCC staging system to guide management and prediction of prognosis in the preoperative setting.